Hangzhou, China, Oct. 10, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that it has received a notification letter from the Nasdaq Stock Market LLC (“Nasdaq”) granting the Company an additional 180-calendar-day period to regain compliance with the minimum bid price requirement pursuan ...

Core Viewpoint - Univest Securities, LLC has successfully closed a $2.9 million registered direct offering for WORK Medical Technology Group LTD, a medical device supplier in China [1][3]. Group 1: Offering Details - The offering involved the sale of 38,999,334 Class A ordinary shares at a purchase price of $0.075 per share [2]. - The gross proceeds from the offering were approximately $2.9 million [3]. - The offering was conducted under a shelf registration statement on Form F-3, which was declared effective by the SEC on September 15, 2025 [4]. Group 2: Company Overview - WORK Medical Technology Group LTD develops and manufactures Class I and II medical devices, with a diverse product portfolio of 21 products, including customized masks and medical consumables [7]. - The company has sold products in 34 provincial-level regions in China and has a presence in over 30 countries worldwide [7]. - WORK Medical Technology has received quality-related manufacturing designations and has registered 17 products with the U.S. FDA, allowing entry into the U.S. market [7]. Group 3: Univest Securities Overview - Univest Securities, LLC has been registered with FINRA since 1994 and provides a variety of financial services, including investment banking and advisory [6]. - The firm has raised over $1.3 billion in capital for issuers globally since 2019 and completed approximately 100 transactions across various industries [6].

Core Viewpoint - WORK Medical Technology Group LTD has entered into a strategic cooperation agreement with the Hong Kong Web3.0 Standardization Association to promote innovation in the Real-world Asset (RWA) sector through resource sharing and complementary strengths [1][4]. Group 1: Strategic Cooperation Agreement - The agreement focuses on collaboration in blockchain solutions, including asset tokenization, equity investment, and RWA technology development [4][5]. - WORK Medical will leverage its capital resources and expertise in medical device manufacturing alongside the Association's resources to advance asset tokenization [4]. - The partnership aims to integrate industrial and financial resources for co-investments to accelerate RWA market expansion [4]. Group 2: Association's Role and Objectives - The Hong Kong Web3.0 Standardization Association is dedicated to supporting the growth of Hong Kong's Web3.0 ecosystem through standardization and research [6]. - The Association's initiatives include promoting technological advancement, establishing standards, and enhancing public awareness of Web3.0 [6]. - The Association launched an RWA registration platform in August 2025 to further its mission [6]. Group 3: Company Profile - WORK Medical develops and manufactures Class I and II medical devices, with a diverse product portfolio of 21 products sold in 34 regions in China and over 30 countries worldwide [8]. - The company has received quality-related manufacturing designations and has registered 17 products with the U.S. FDA for market entry in the U.S. [8].

Core Viewpoint - WORK Medical Technology Group LTD has signed a strategic cooperation agreement with Xin Rui Hospital to develop AI-driven medical products, aiming to enhance the digital healthcare ecosystem in China [1][2][4]. Group 1: Agreement Details - The agreement involves Work Hangzhou supporting Xin Rui Hospital in advancing hospital informatization and the application of AI-powered medical products [2]. - The collaboration aims to integrate AI technology with various medical resources at Xin Rui Hospital, including text, imaging, and laboratory data, to create a digital knowledge base for intelligent healthcare [2]. - The partnership is expected to enhance the development and clinical application of AI models across multiple healthcare scenarios, focusing on data governance, model training, and translating research into clinical practice [2]. Group 2: Company Background - WORK Medical Technology Group LTD, through its subsidiary Work (Hangzhou) Medical Treatment Equipment Co., Ltd., develops and manufactures Class I and II medical devices, with a diverse product portfolio of 21 items [5]. - The company has products sold in 34 provincial-level regions in China and has registered 17 products with the U.S. Food and Drug Administration, allowing entry into the U.S. market [5]. Group 3: Leadership Perspective - The CEO of WORK Medical expressed enthusiasm about the partnership, highlighting the goal of establishing a model for hospital digitalization and intelligent healthcare applications [4]. - The collaboration is anticipated to accelerate AI transformation in domestic hospitals and broaden the adoption of technology solutions [4].

Core Viewpoint - WORK Medical Technology Group LTD is conducting a registered offering of 10,000,000 ordinary and pre-funded units to raise funds for various corporate purposes, including upgrading production equipment and R&D investments [1][3]. Group 1: Offering Details - The offering price is set at $0.50 per Ordinary Unit and $0.4995 per Pre-funded Unit [1]. - Each Ordinary Unit includes one Class A ordinary share, one Series A warrant, and one Series B warrant, while each Pre-funded Unit consists of one pre-funded warrant, one Series A warrant, and one Series B warrant [2]. - The Company expects to receive gross proceeds of $5.0 million from the offering before deducting expenses [3]. Group 2: Use of Proceeds - Proceeds will be allocated for upgrading production equipment, investing in R&D, hiring experienced employees for compliance improvements, and general corporate purposes [3]. Group 3: Company Overview - WORK Medical is a supplier of medical devices in China, developing and manufacturing Class I and II medical devices, with a diverse product portfolio of 21 products [6]. - The Company has sold products in 34 provincial-level regions in China and in over 30 countries globally, with 17 products registered with the U.S. FDA [6].

Core Viewpoint - WORK Medical Technology Group LTD has announced a strategic partnership with Shanghai Chartwell Medical Device Co., Ltd to enhance growth and innovation in the healthcare sector [1][2]. Company Overview - WORK Medical Technology Group LTD is a supplier of Class I and II medical devices, with a diverse product portfolio of 21 products, including customized masks and medical consumables, sold in 34 provincial-level regions in China and over 30 countries globally [3]. - The company has received multiple quality-related manufacturing designations and has registered 17 products with the U.S. FDA, allowing entry into the U.S. market [3]. Partnership Details - The collaboration will involve Chartwell Medical's subsidiaries, including Fuying and Fufeng, focusing on mutual growth and unlocking new opportunities [2]. - The partnership aims to enhance operational efficiency, market leadership, and international competitiveness, with a goal to advance high-end medical technologies [2]. - Specific cooperation projects are expected to enrich WORK Medical's product portfolio and increase the proportion of high-value-added products, leading to substantial growth in revenue and profits over the next three years [2]. Strategic Initiatives - The partnership will explore joint investment funds to align industrial and financial resources, including potential investments in Chartwell Medical or merging it into WORK Medical [6]. - Future co-investments are planned in key projects such as healthcare infrastructure, advanced technology R&D, and global acquisitions [6]. Chartwell Medical Overview - Shanghai Chartwell Medical Device Co., Ltd specializes in high-end medical devices and consumables, serving the Asia-Pacific region with a diverse portfolio across multiple categories [4]. - The company holds exclusive agency rights for several leading high-end medical brands from Japan, enhancing its market position [4].